Open AccessLutetium in prostate cancer: Reconstruction of patient-level data from published trials and generation of a multi-trial Kaplan-Meier curve
Author(s) -
Andrea Messori
Publication year - 2022
Publication title -
world journal of methodology
Language(s) - English
Resource type - Journals
ISSN - 2222-0682
DOI - 10.5662/wjm.v12.i3.107
Subject(s) - lutetium , prostate cancer , medicine , clinical trial , prostate , overall survival , hazard ratio , oncology , cancer , medical physics , confidence interval , chemistry , organic chemistry , yttrium , oxide
Lutetium has been shown to be an important potential innovation in pre-treated metastatic castration-resistant prostate cancer. Two clinical trials have evaluated lutetium thus far (therap and vision with 99 and 385 patients, respectively), but their results are discordant.